Back
Protagonist Therapeutics Stock Price Chart
Sponsored
PTGX
Sponsored
Biden's Oil War: The Administration Is All-In on Green Energy.
Download Free Report
Sell
48
PTGX
Protagonist Therapeutics
Last Price:
28.49
Seasonality Move:
24.27%
7 Day Trial
ALL ACCESS PASS
$
7
Billionaire Investors Join Forces to Fund Next Generation
Learn More- The current trend is relatively stagnant and PTGX is experiencing buying pressure, which is a positive indicator for future bullish movement.
Protagonist Therapeutics Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 28.36 | Buy |
20-day SMA: | 29.6 | Sell |
50-day SMA: | 27.81 | Buy |
200-day SMA: | 21.75 | Buy |
8-day EMA: | 28.46 | Buy |
20-day EMA: | 28.79 | Sell |
50-day EMA: | 27.5 | Buy |
200-day EMA: | 22.71 | Buy |
Protagonist Therapeutics Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 0 | Buy |
Relative Strength Index (14 RSI): | 48.84 | Sell |
Chaikin Money Flow: | 211353 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (28.26 - 30.76) | Sell |
Bollinger Bands (100): | (19.04 - 28.62) | Buy |
Protagonist Therapeutics Technical Analysis
Mar 14 | Mar 15 | Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 22 | Mar 25 | Mar 26 | Mar 27 | |
---|---|---|---|---|---|---|---|---|---|---|
Mar | ||||||||||
14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Protagonist Therapeutics Stock
Is Protagonist Therapeutics Stock a Buy?
- Protagonist Therapeutics share price is 28.48 while PTGX 8-day simple moving average is 28.36, which is a Buy signal.
- The stock price of PTGX is 28.48 while Protagonist Therapeutics 20-day SMA is 29.60, which makes it a Sell.
- Protagonist Therapeutics 50-day simple moving average is 27.81 while PTGX share price is 28.48, making it a Buy technically.
- PTGX stock price is 28.48 and Protagonist Therapeutics 200-day simple moving average is 21.75, creating a Buy signal.
PTGX Technical Analysis vs Fundamental Analysis
Sell
48
Protagonist Therapeutics (PTGX)
is a Sell
Is Protagonist Therapeutics a Buy or a Sell?
-
Protagonist Therapeutics stock is rated a Sell
The current Protagonist Therapeutics [PTGX] share price is $28.48. The Score for PTGX is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
Protagonist Therapeutics Stock Info
Market Cap:
1.66B
Price in USD:
28.48
Share Volume:
359.3K
Protagonist Therapeutics 52-Week Range
52-Week High:
33.34
52-Week Low:
13.72
Sell
48
Protagonist Therapeutics (PTGX)
is a Sell
Protagonist Therapeutics Share Price Forecast
-
What is the Protagonist Therapeutics stock price today?
The Protagonist Therapeutics stock price is 28.48 USD today. -
Will PTGX stock go up or go down?
Protagonist Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Protagonist Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Protagonist Therapeutics is overvalued.
Is Protagonist Therapeutics Stock a Buy?
- Protagonist Therapeutics share price is 28.48 while PTGX 8-day exponential moving average is 28.46, which is a Buy signal.
- The stock price of PTGX is 28.48 while Protagonist Therapeutics 20-day EMA is 28.79, which makes it a Sell.
- Protagonist Therapeutics 50-day exponential moving average is 27.50 while PTGX share price is 28.48, making it a Buy technically.
- PTGX stock price is 28.48 and Protagonist Therapeutics 200-day simple moving average is 22.71, creating a Buy signal.
Fundamental Analysis of Protagonist Therapeutics
Is Protagonist Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.10 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.87 per share, and a decrease next year of $0.23 per share.
Technical Analysis of Protagonist Therapeutics
Should I short Protagonist Therapeutics stock?
- PTGX Moving Average Covergence Divergence (MACD) indicator is 0, suggesting Protagonist Therapeutics is a Buy
- Protagonist Therapeutics Relative Strength Index (RSI) is 48.84, which suggest Protagonist Therapeutics is oversold
- The Bollinger Bands (25) for Protagonist Therapeutics is (28.26 - 30.76), which suggest Protagonist Therapeutics is a Buy
- The Bollinger Bands (100) for Protagonist Therapeutics is (19.04 - 28.62), which suggest Protagonist Therapeutics is a Buy
* Protagonist Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.